Welcome to our dedicated page for MindWalk Holdings news (Ticker: HYFT), a resource for investors and traders seeking the latest updates and insights on MindWalk Holdings stock.
MindWalk Holdings Corp. reports developments in Bio-Native AI drug discovery, biologics research, and AI-driven therapeutic development. Company updates center on its patented HYFT technology and LensAI platform, which combine biological sequence, structure, function, literature analysis, and wet-lab validation for biologics discovery workflows.
Recurring news themes include financial results, enterprise platform contracts, North American biologics services activity, and product or program updates. Announcements have covered B Cell Llama for VHH nanobody discovery, B Cell Select, universal influenza research, functional-adjacency analysis for AI-designed therapeutics, and antibody or intrabody discovery work involving pathogenic TDP-43 in neurodegenerative disease.
MindWalk Holdings (NASDAQ: HYFT) presented the first public demonstration of its ReefIQ™ biological context layer for AI drug discovery running on AMD Instinct™ at AMD’s Advancing AI 2026 event in San Francisco. The demo, part of the AMD Instinct Demo Showcase, was accompanied by an AMD-distributed video interview.
ReefIQ, introduced in June 2026, sits between client discovery data and AI workflows, reconnecting fragmented biological data into governed, queryable context that AI models and agents can reason over. Built on MindWalk’s HYFT® biological pattern technology and exposed to LensAI™, it aims to preserve program knowledge, support regulated governance, and run on open, memory-rich AMD Instinct infrastructure.
MindWalk Holdings (NASDAQ: HYFT) reported fiscal 2026 revenue of $15.6 million, up 46% from $10.6 million, with gross profit rising to $9.1 million and gross margin expanding to 58.8% from 53.9%. Net loss from continuing operations narrowed to $15.1 million from $33.1 million, while loss per share from continuing operations improved to $0.33 from $0.99.
According to MindWalk, total operating expenses declined 44% to $24.1 million, mainly due to the non-recurrence of about $22.7 million of prior-year non-cash amortization and impairment charges. The company divested its Netherlands subsidiary, generating approximately $14.3 million in proceeds, completed its rebranding to MindWalk Holdings to reflect its Bio-Native AI focus, regained Nasdaq compliance, and authorized a discretionary buyback of up to 2.3 million shares (~5% of shares then outstanding). It also signed its first two recurring LensAI platform contracts and, after year-end, launched its ReefIQ context layer and was added to the Russell 3000E and Russell Microcap indexes.
MindWalk Holdings (NASDAQ: HYFT), a Bio-Native AI company, will report financial results for its fourth quarter and full fiscal year 2026 on Wednesday, July 22, 2026, at 5:00 p.m. Eastern Time. The company will host an earnings conference call with a management presentation and Q&A.
The financial results will be released in a press release before the call. The live webcast and replay will be accessible via the Events section of MindWalk’s investor relations site. Participants can also join by phone using the provided U.S. and Canadian toll and toll-free dial-in numbers.
MindWalk Holdings (NASDAQ: HYFT) has been added to the Russell 3000E Index, effective after the U.S. market close on June 26, 2026, following FTSE Russell’s June 2026 semi-annual reconstitution.
The index covers up to 4,000 large U.S. companies, with about $12.2 trillion benchmarked to Russell US Indexes, expanding HYFT’s visibility and eligibility among institutional and index-tracking investors.
MindWalk (NASDAQ: HYFT) filed European patent application EP26187897.9 for a high-dimensional biological data architecture underpinning its HYFT® Technology, ReefIQ™ context layer, and LensAI™ reasoning workflows.
The model-agnostic layer is designed to organize reusable biological meaning for AI-enabled drug discovery across customer programs and platforms.
Absci (NASDAQ: ABSI) will participate in a Jones AI Day virtual panel on June 15, 2026, at 12:00 p.m. ET, alongside MindWalk (NASDAQ: HYFT) and a leading AI compute provider.
The discussion will cover AI, biological knowledge, and high-performance compute in drug discovery.
Summary not available.
MindWalk (Nasdaq: HYFT) reported preclinical dengue data supporting a HYFT® computational prediction. HYFT® identified a candidate pan-serotype dengue target before immunization; immunogens designed on this target elicited antibodies that cross-reacted with antigens from all four dengue serotypes, reproduced across two independent campaigns. Scrambled controls lacked similar cross-serotype recognition, indicating specificity to the designed immunogen.
The experimentally supported target now anchors MindWalk's dengue pipeline IP within its Biointelligence Platform, and the same predictive capability is being applied to influenza and other multi-strain infectious disease programs.
MindWalk Holdings (NASDAQ: HYFT) launched its Pandemic Response Platform, a HYFT® and LensAI™ configuration for outbreak preparedness and rapid countermeasure design against RNA viruses, announced May 27, 2026.
The platform targets conserved viral architecture instead of mutable surface proteins and is already deployed on wholly owned pan-serotype Dengue and universal Influenza programs at in vivo proof-of-concept stage. It builds on an infrastructure that has supported over 20 molecules advanced to the clinic and uses The Knowledge Graph with 660 million biological patterns and 25 billion relationships to identify structurally constrained targets across evolving RNA virus families.
MindWalk Holdings (NASDAQ: HYFT) reported that over 20 drug candidates in partner pipelines originated from its antibody discovery work, with 10 programs now in active Phase 1–3 clinical trials across oncology, immunology, neurology, and infectious disease.
The company highlighted its HYFT® and LensAI™ biological intelligence infrastructure, built on a Knowledge Graph indexing 660 million biological patterns and 25 billion relationships, and a record of 400+ peer-reviewed publications and patents supporting collaborations with firms such as Annexon, argenx, Xencor, Cullinan Oncology, and others.